Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-06-05 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司独立董事提名人声明（高燕萍）
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of directors of Jinling Pharmaceutical Co., Ltd. nominating an independent director candidate. It details the nominee's qualifications, compliance with various regulatory requirements, and declarations regarding independence and eligibility. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the nomination of a new independent director. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2023-06-05 Chinese
金陵药业股份有限公司独立董事候选人声明（寇俊萍）
Board/Management Information Classification · 95% confidence The document is a public statement by an independent director candidate of Jinling Pharmaceutical Co., Ltd. It contains detailed declarations about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. There are no financial statements, earnings data, or management discussions. The content is focused on governance and compliance related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to announcements about board members or candidates.
2023-06-05 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票方案论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "年度向特定对象发行 A 股股票方案论证分析报告" which translates to "Annual Report on the Proposal and Analysis of Non-public Issuance of A Shares." It is issued by Jinling Pharmaceutical Co., Ltd. and dated 2023. The content discusses the company's plan to issue A shares to specific investors, including the background, purpose, pricing, legal compliance, and impact on shareholders. It includes detailed financial projections and regulatory compliance references. This is a detailed report analyzing a capital raising plan through a non-public share issuance, which fits the category of Capital/Financing Update (CAP). The document is lengthy (over 14,000 characters) and contains substantive analysis and financial data related to the financing activity, not just an announcement or summary. Therefore, the appropriate classification is CAP with high confidence.
2023-05-29 Chinese
金陵药业关于2023年度向特定对象发行A股股票预案及相关文件修订情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the revision of a 2023 plan for a specific issuance of A shares by Jinling Pharmaceutical Co., Ltd. It details updates to the issuance plan, feasibility analysis reports, and pricing analysis reports. The document is relatively short (2790 characters) and primarily describes amendments to the issuance plan and related documents, referencing prior announcements and approvals. It does not contain actual financial statements or detailed financial data but rather updates and explanations about the capital raising plan and related approvals. This fits the category of a Capital/Financing Update (CAP), as it concerns updates on company fundraising activities and capital structure changes.
2023-05-29 Chinese
金陵药业股份有限公司第八届董事会第三十二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 32nd meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes voting results, descriptions of agenda items related to adjustments in a specific share issuance plan, and references to related announcements and reports published elsewhere. The content focuses on board decisions regarding a capital raising activity through a targeted issuance of A shares, including amendments to the issuance plan and related agreements. There is no presentation of financial statements or comprehensive financial data, nor is it a full annual or interim report. The document is not a simple announcement of a report publication but a substantive disclosure of board resolutions related to financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (3509 characters) is relatively short but contains detailed board meeting resolutions and voting results on financing matters, not just a brief notice or regulatory filing. Hence, the classification is CAP with high confidence.
2023-05-29 Chinese
金陵药业股份有限公司独立董事关于公司第八届董事会第三十二次会议审议的有关议案的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion on various proposals related to a specific capital raising activity, namely a targeted issuance of A shares in 2023. It discusses the legality, fairness, and compliance of the issuance plan, feasibility reports, dilution impact, and related agreements. The document references relevant laws and regulations and confirms the board's approval process. The content is focused on the independent directors' review and opinion on the capital raising proposals rather than the capital raising announcement itself or a full financial report. Given the focus on the issuance of shares and related approvals, this document fits best under Capital/Financing Update (CAP). The document length is short (2190 characters), but it contains substantive independent opinions on financing proposals, not just an announcement or a certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2023-05-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.